Abstract
Introduction
Over the last thirty years, complexes of Bisphosphonate analogs have a high affinity for hydroxyapatite and accumulate in bone because their phosphonate groups bind to the Ca 2+ of hydroxyapatite crystals [5] . In the cases of Tc-MDP and 99m Tc-HMDP, the phosphonate groups coordinate with technetium [6] , which might decrease the inherent accumulation of MDP and HMDP in bone. Thus, we hypothesized that the bone affinity of technetium-99m labeled bisphosphonate would be increased by the design of a bisphosphonate in which the phosphonate groups do not coordinate with technetium-99m. To enable imaging at an earlier time after injection, we and other groups have designed technetium-99m complex-conjugated bisphosphonate compounds based on the concept of bifunctional radiopharmaceuticals [7] [8] [9] [10] . As we expected, some of the novel technetium-99m complex-conjugated
Ogawa et al. 6/35 bisphosphonate compounds showed superior biodistribution compared with previous compounds. This drug concept is applicable not only to technetium complex radiopharmaceuticals but also to other metals, such as rhenium [11] [12] [13] [14] [15] [16] [17] [18] , lutetium [19] , yttrium [20] , gadolinium [21] , and so on. 68 Ga is one of the greatest practical and interesting radionuclides for clinical positron emission tomography (PET) because of its radiophysical properties (T 1/2 = 68 min) [22] . 68 Ga is a generator-produced nuclide and can be eluted at any time on demand. Specifically, it does not require an on-site cyclotron. In principle, the long half-life of the parent nuclide 68 Ge (T 1/2 = 270.8 days) provides a long life-span generator.
In this study, to develop a new tracer with radiogallium for the imaging of bone disorders such as bone metastases, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was chosen as a chelating site because it has been well known that Ga forms a stable complex with DOTA. Therefore, Ga-DOTA-conjugated bisphosphonate was designed, and evaluated by in vitro and in vivo experiments. Although we are interested in developing 68 Ga labeled bone imaging agents for PET, in these initial studieslonger half-life.
Materials and methods

Materials
Proton nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a JEOL JNM-ECS600 spectrometer (JEOL Ltd., Tokyo, Japan) and the chemical shifts were reported in ppm downfield from an internal tetramethylsilane standard. Electrospray ionization mass spectra (ESI-MS)
were obtained with an LCQ (Thermo Fisher Scientific, Waltham, MA). 2-4-Isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraace tic acid (p-SCN-Bn-DOTA) was purchased from Macrocyclics (Dallas, TX).
Other reagents were of reagent grade and used as received. 
In vitro stability
To evaluate the stability of 67 Ga-DOTA-Bn-SCN-HBP in buffered-solution, 67 Ga-DOTA-Bn-SCN-HBP (100 μL) was diluted with 0.1 M phosphate buffer (pH 7.4, 400 μL) and the solution was incubated at 37˚C. 
Hydroxyapatite-binding assays
Hydroxyapatite-binding assays were performed according to procedures described previously with slight modification [23] . In brief, hydroxyapatite beads (Bio-Gel; Bio-Rad, Hercules, CA) were suspended in Tris/HCl-buffered saline (50 mM, pH 7.4) at 1 mg/mL, 10 mg/mL, and 25 mg/mL. For the solutions of 67 Ga-labeled compounds ( 67 Ga-DOTA-Bn-SCN-HBP and 67 Ga-DOTA), the ligand concentrations were adjusted to 19.5 µM. Two hundred microliters of each solution of temperature. This period was used because it has been reported that 1 h is sufficient to attain binding equilibrium [23] . After centrifugation at 10,000g
for 5 minutes, the radioactivity of the supernatant was measured with an auto well gamma counter (ARC-7010B, Aloka, Tokyo, Japan). Control experiments were performed using the same procedure but without the hydroxyapatite beads. In the control experiments, we confirmed that the radioactivity adsorbed to the vials was less than 0.1%. The rate of binding was determined as follows:
Hydroxyapatite binding (%) = (1 -[radioactivity of supernatant of each sample]/[radioactivity of supernatant in the respective control]) × 100
Biodistribution experiments
Experiments with animals were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals of Kanazawa University. Biodistribution experiments were performed with an intravenous administration of each diluted tracer solution (37 kBq / 100 μL) to 6-week-old male ddY mice (27-32 g, Japan SLC, Inc., Hamamatsu, Japan).
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To investigate the effect of an excess amount of bisphosphonate on biodistribution, alendronate (40 mg/kg) was intravenously administered to mice 1 minute before the intravenous injection of 67 Ga-DOTA-Bn-SCN-HBP. Four or five mice each were sacrificed by decapitation at 10, 60, and 180 minutes postinjection of the radiotracer.
Tissues of interest were removed and weighed. The complete left femur was isolated as a representative bone sample. The levels of radioactivity in these tissues were determined with an auto well gamma counter and corrected for background radiation and physical decay during counting.
Statistical analysis
Data are expressed as mean ± standard deviation, where appropriate.
The results were statistically analyzed using unpaired Students' t test; p = 0.05 was set as the level of significance.
Results
Preparation of 67 Ga-labeled compounds
DOTA-Bn-SCN-HBP (3) as a precursor was synthesized by a After 24 hours of incubation in plasma, 80.2 ± 1.0% of 67 Ga-DOTA-Bn-SCN-HBP remained intact. 
In vitro stability
Hydroxyapatite-binding assay
Biodistribution experiments
The biodistributions of 67 Ga-DOTA-Bn-SCN-HBP and 67 Ga-DOTA in normal mice are presented in Tables 1 and 3, respectively. 67 Ga-DOTA-Bn-SCN-HBP showed a high degree of accumulation in bone soon after injection, and almost all other radioactivity was quickly excreted via the kidneys. Consequently, radioactivity was scarcely observed in any tissue without bone at 60 minutes after injection. Meanwhile, 67 Ga-DOTA did not accumulate in bone, and almost all injected radioactivity was quickly excreted via the kidneys.
The biodistributions of 67 Ga-DOTA-Bn-SCN-HBP with pretreatment of alendronate (40 mg/kg) in normal mice is presented in Table 2 .
Pretreatment of alendronate inhibited bone accumulation of 67 Ga-DOTA-Bn-SCN-HBP and caused an increase in radioactivity levels in most organs except bone, muscle, and brain. Investigations of 68 Ga-labeled compounds for bone imaging were previously described in the 1970s [25, 26] . In these reports, gallium was Ga-EDTMP was re-evaluated by Mitterrhauser et al. [28] . However, they stated that the advantage of 68 Ga-EDTMP over (Tables 1 and 4) , because it has long been used as a design as a bone-seeking radiopharmaceutical because DOTA-Bn-SCN-HBP has a hydroxyl group (α-OH group) at a central carbon of the bisphosphonate structure. On the other hand, BPAMD does not have an α-OH group. Previous studies of bisphosphonates suggest that the presence of the α-OH group affects affinity for bone minerals [30] . In the design of radiometal complex-conjugated bisphosphonate derivatives, it has also been suggested that the α-OH group is effective in enhancing accumulation in bone [12] .
Discussion
In conclusion, a 67 Ga DOTA complex-conjugated bisphosphonate derivative,
67
Ga-DOTA-Bn-SCN-HBP, showed ideal biodistribution characteristics as a bone scintigraphy agent. These findings should provide useful information on the drug design of PET tracers with 68 Ga for diagnosis and as a monitor for the therapy of bone disorders, such as bone metastases.
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